A team of researchers from the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), the Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC), and the Instituto de Ciencias ...

PALO ALTO, Calif., Jan. 18, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare ...

A team of scientists from the CNIC and the CSIC has identified a key mechanism in the development of atherosclerosis in patients with the rare genetic disease Hutchinson-Gilford progeria syndrome The ...

“The findings highlight miRNA-145-5p and miRNA-27b-3p as potential therapeutic targets to address adipose tissue defects and premature aging in HGPS” “The findings highlight miRNA-145-5p and miRNA-27b ...

Sentynl, a Zydus Group company, receives worldwide proprietary rights to Zokinvy, adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases Zokinvy is approved in the U.S. (2020), ...

Learn about Progeria, a rare genetic disorder causing premature ageing in children—explore symptoms, diagnosis, treatment ...

A new article could spur the development of new and improved treatments for Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder with no known cure that causes accelerated aging in ...

Leslie Gordon's son Sam was 22 months old when he was diagnosed with Hutchinson-Gilford Progeria syndrome, a devastating disease in which children age rapidly and usually die between their 7th and ...

In the spring of 2005, families affected by progeria welcomed the news from two studies that uncovered new information about this rare, devastating condition that causes premature aging in children.

Collectively known as progeria, Hutchinson-Gilford progeria syndrome and progeroid laminopathies are ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients.